GENMAB AND ABBVIE SAY EPCORITAMAB IN COMBINATION WITH R-CHOP DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), WITH THE PHASE 3 TRIAL SHOWING A 51% REDUCTION IN THE RISK OF PROGRESSION OR DEATH